Gas Industry | Gas Infrastructure in Europe

This report investigates the current position of gas infrastructure in Europe and the current state of gas pipelines and projects in the region.

Features and benefits

• Analyze the legislation surrounding the gas industry in Europe.
• Analyze the major gas pipelines impacting Europe.
• Analyze the major gas projects impacting Europe.
• Understand the demand and supply dynamics of the gas market in Europe.
• Understand the major drivers behind the growing gas market in Europe and who the major suppliers will be.

Highlights
The EU possesses only 1.6% of the world’s proved natural gas reserves, and produces only 6.2% of the total production on earth, making imports a necessity now and in the foreseeable future. Natural gas is likely to become the energy source of choice in Europe after Germany and other countries decided to abandon nuclear energy.
Russia is the owner of proven natural gas reserves estimated at 1,680tcf located mainly in Siberia and is also the world’s second largest producer of natural gas after the US, and the EU’s largest external supplier. Four of Russia’s seven major export pipelines move product to Europe and have a combined capacity of 4.0 tcf.
Shale gas refers to natural gas trapped within shale formations. The two key pieces of legislation at EU level that apply to shale gas activities are the Hydrocarbons Directive and REACH. Very little specific legislation or regulation, either at an EU or member-state level, currently exists regarding shale gas activities.

Request a Sample @ http://www.reportsnreports.com/reports/159567-gas-infrastructure-in-europe.html

Report Details:
Published: April 2012
No. of Pages: 133
Price: Single User License: US $ 2875          Corporate User License: US $ 10781



Few Points Covered in Table of Contents
About the author
Disclaimer
EXECUTIVE SUMMARY
European gas market
Legislation and regulation in the gas industry
Major gas pipelines in Europe
Major gas projects in Europe
Future outlook for gas infrastructure in Europe
European gas market
Summary
World gas reserves/European gas reserves
European proximity to major suppliers
Relations with Russia
Supply capacities
Size of the gas market in Europe
Use of gas in power generation
Gas and sustainability
Gas market in Europe
Germany
Italy
The Netherlands
Norway
Russia
Spain
The UK
Legislation and regulation in the gas industry
Summary
Shale gas and fracking
Legislation and regulation overview
Hydrocarbons Directive
REACH
Current status of shale legislation
Country-specific developments
Carbon emissions
The Kyoto Protocol
The 20-20-20 Targets
EU Emissions Trading System
The Copenhagen Accord, December 2009
Climate and Energy Package, December 2008
Shale gas and fracking emissions
Transit and storage
EU Transit Protocol
Timeline of transit and storage legislation
Problems with EU policy
Other relevant legislation for the gas sector
Storage and supply

UK 2012 Consumer Satisfaction Index Homewares

UK Consumer Satisfaction Index 2012 for homewares is based around individual retailers and provides a highly detailed, data-rich overview of a retailer's customers, drawing on a nationwide survey of 6,000 shoppers each year.

Features and benefits

• Measures and ranks customer satisfaction for all significant retailers in the sector over six years (2007-2012)
• Includes ratings for price, range, quality, service, convenience, ambience, layout and facilities. Use these to understand strengths and weaknesses
• Identifies the biggest CSI winners and losers in homewares this year, highlighting those that pose the greatest threat to your business

Your key questions answered

• What is driving satisfaction for different retailers in homewares? Which retailers have improved the most?
• What are your competitors' strengths and weaknesses and how can you exploit them by adapting your own strategies?
• How are drivers of satisfaction changing in terms of importance in the consumers' eyes? What impact is the economy having on drivers of satisfaction?

Get Your Copy of Report @ http://www.reportsnreports.com/reports/159565-uk-consumer-satisfaction-index-2012-homewares.html

Report Details:
Published: May 2012
No. of Pages: 19
Price: Single User License: US $ 5250          Corporate User License: US $ 13125




Few Points from Table of Contents
EXECUTIVE SUMMARY
About CSI
Summary of findings – Homewares
Strong range leaves IKEA top as John Lewis slides to third
Wilkinson remains top for price and rises five places overall
Convenience snapped up by Sainsbury's
Marks & Spencer makes biggest quality gains, displacing John Lewis
John Lewis still outscores on service
Gains made in ambience at expense of Dunelm Mill
SYNOPSIS AND COMPARATIVES
Homewares
RANKINGS
Overall ranking – homewares
Winners since last year – homewares
Losers since last year – homewares
Rankings for range – homewares
Rankings for price – homewares
Rankings for convenience – homewares
Rankings for quality – homewares
Rankings for service – homewares
Rankings for ambience – homewares
Rankings for facilities – homewares
Rankings for layout – homewares

Browse all Consumer Related Reports @ http://www.reportsnreports.com/market-research/consumer-goods/

Pharmarceutical Report | Product Profiles: Insulin Antidiabetics – Key developers compete for basal insulins market

The basal insulins are the most successful insulin class, with other insulin classes demonstrating high substitution or low and declining sales. Current basal insulins offer good safety and emerging therapies are not expected to improve efficacy significantly. However, the launch of two late-stage pipeline products Degludec and DegludecPlus in 2012–13 will alter market dynamics.
Features and benefits

• Understand Datamonitor’s independent appraisal of marketed insulin brands and key pipeline agents indicated for treating type 1 and type 2 diabetes.
• Illustrate how pipeline and marketed insulins compare to one another in terms of clinical and commercial attributes.
• Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
• Understand how marketed insulin brands are positioned in the diabetes treatment algorithm and how they are perceived by prescribers.
• Determine to what extent future insulin therapies satisfy the main clinical unmet needs in the treatment of type 1 and type 2 diabetes.

Highlights
With strong marketing and sales resources committed by Novo Nordisk, late-stage basal insulin Degludec (insulin degludec) will offer strong competition to class leader Lantus (insulin glargine; Sanofi) and largely cannibalize predecessor Levemir (insulin detemir; Novo Nordisk).
Key patents for blockbuster Lantus will expire from 2014–15. However, the threat of biosimilar insulin is expected to have less impact than typical small molecule generics, as physicians are expected to be reluctant to introduce potential additional variability into patients’ insulin treatment regimens.

Buy Your Copy of Report @ http://www.reportsnreports.com/reports/159563-product-profiles-insulin-antidiabetics-key-developers-compete-for-basal-insulins-market.html 

Report Details:
Published: April 2012
No. of Pages: 65
Price: Single User License: US $ 7600          Corporate User License: US $ 19000




Table of Contents
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Related reports
Published diabetes reports
PRODUCT OVERVIEW
Insulin use in type 1 and type 2 diabetes
Insulin coverage in this report
MARKETED PRODUCT PROFILES
Basal insulin class overview
Lantus (insulin glargine; Sanofi)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Lantus
Clinical and commercial attractiveness
Levemir (insulin detemir; Novo Nordisk)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Levemir
Clinical and commercial attractiveness
Other marketed insulin antidiabetics
Fast-acting insulins
Premixed insulins
PIPELINE PRODUCT PROFILES
Degludec (insulin degludec; Novo Nordisk)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Other insulin antidiabetics in development
LY2605541 (Eli Lilly/Boehringer Ingelheim)
Improved basal insulin formulations
Non-injected insulin formulations

Browse all Reports related to Pharmaceuticals @ http://www.reportsnreports.com/market-research/pharmaceuticals/